Indication: Squamous Cell Carcinoma

A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)

Recurrent Cutaneous

Sub-indication: CSCC

Line of Therapy: Second or Third Line

Drug Study

Principal Investigator: Jae Jung, M.D.
Norton Cancer Institute

Sponsor: Regeneron Pharmaceuticals, Inc.

Email for more information: Derm-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.